Kopran Ltd

Kopran, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low amid significant volatility, with an intraday decline of 5.5%. The stock has faced consecutive losses over four days, trailing its sector and showing a 35.66% decline over the past year.

Kopran has announced its financial results for the quarter ending February 2025, revealing a challenging performance for Q3 FY24-25. Despite these difficulties, the company's evaluation score has remained stable over the past three months, indicating no significant changes in its overall financial assessment. Stakeholders should monitor future developments closely.

Kopran, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, reflecting a significant decline over recent days. The stock has underperformed compared to its sector and has consistently traded below key moving averages, indicating ongoing challenges in its market performance over the past year.

Kopran, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, reflecting a challenging year with a 31.75% decline. The stock is trading below its moving averages, indicating a sustained downward trend, as the company faces ongoing market pressures.

Kopran, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, reflecting a challenging year with a 31.75% decline. The stock is trading below its moving averages, indicating a sustained downward trend, as the company faces ongoing market pressures.

Kopran, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, reflecting a challenging year with a 31.75% decline. The stock is trading below its moving averages, indicating a sustained downward trend, as the company faces ongoing market pressures.

Kopran, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, continuing a downward trend with a 10.6% decline over five days. The stock is underperforming compared to the broader market, reflecting ongoing challenges in a competitive environment.

Kopran Ltd, a microcap pharmaceutical company, has hit a new 52-week low, with its stock price at Rs. 187.05. The stock has consistently declined over the past five days and is trading below multiple moving averages, reflecting ongoing challenges in the market and a significant year-over-year decline.

Kopran Ltd has reached a new 52-week low, with its stock price falling to Rs. 193.05 on January 13, 2025. The company has underperformed its sector and experienced a consecutive decline over the past four days. Its annual performance shows a significant decline compared to the Sensex.

On November 22, 2024, Kopran, a smallcap pharmaceutical company, experienced a significant increase in its stock price, outperforming the sector by 8.73%. This comes after six consecutive days of decline, indicating a possible trend reversal. The stock is currently trading below its moving averages and has been highly volatile today. MarketsMOJO has given a 'Sell' call for the stock, but this is not a recommendation. Kopran specializes in drug production and has shown promising growth in the past.

Kopran, a microcap pharmaceutical company, has hit a 52-week low on November 21, 2024, with a consecutive fall of -34.71% in returns over the past 6 days. The stock is currently trading below its moving averages and has underperformed the market by -25.40% in the past year. According to MarketsMOJO, the stock call for Kopran is 'Sell'.

Kopran, a smallcap pharmaceutical company, has been experiencing a downward trend in its stock performance. On November 19, 2024, the stock lost 7.2% of its value and is currently trading close to its 52-week low. The stock has underperformed the sector for five consecutive days and is trading below its moving averages, indicating a negative trend. Investors are advised to carefully consider all factors before making any investment decisions.

Kopran, a smallcap pharmaceutical company, has been downgraded to 'Sell' by MarketsMOJO due to poor long-term growth and negative results in September 2024. The stock has underperformed the BSE 500 and has a low operating profit to interest ratio. However, it has a strong ability to service debt and institutional investors have increased their stake. Investors should carefully consider all factors before making any decisions.

Kopran's operating cash flow has been consistently growing, but there are concerning factors such as a declining operating profit to interest ratio and declining PBT and PAT.

Kopran, a smallcap pharmaceutical company, has seen a decline in its stock price, losing -7.64% on November 13, 2024. This marks the second consecutive day of losses, with a total decline of -10.71%. Despite performing better than the 200 day moving average, Kopran's stock has underperformed the market. MarketsMOJO has given a 'Hold' call for the stock, advising investors to do their own research before investing.

Kopran, a smallcap pharmaceutical company, has been downgraded to a 'Hold' by MarketsMOJO due to concerns about its long-term growth. However, the company has a strong ability to manage debt, positive financial results, and a bullish technical outlook. Institutional investors have also shown confidence in the company. Investors are advised to monitor closely.

Kopran, a smallcap pharmaceutical company, has been upgraded to a 'Buy' recommendation by MarketsMOJO due to its strong ability to manage debt, positive financial results, and bullish technical trend. The stock is currently trading at a discount and has seen an increase in institutional investor interest. However, long-term growth may be a concern.

On November 5th, 2024, Kopran, a smallcap pharmaceutical company, saw a 7.08% increase in its stock price, outperforming the sector by 7.59%. The stock also opened with a gain of 2.71% and reached an intraday high of Rs 313.5. Its moving averages are higher than the 5-day, 20-day, 100-day, and 200-day averages, indicating a positive trend. Kopran's stock has also outperformed the Sensex in the past month, with a 'Hold' call from MarketsMOJO.

Kopran, a smallcap pharmaceutical company, has been downgraded to a 'Hold' by MarketsMOJO due to its current financial performance and market trends. However, the company has a strong ability to service debt and has shown positive results in the last four quarters. Institutional investors have also shown interest, but long-term growth may be a concern.